ZyVersa Therapeutics, Inc.
ZVSA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001859007
No open-market purchases or sales by ZyVersa Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding ZyVersa Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 21 | 25 | +4 |
| Shares | 5.58M | 6.26M | +679.9K (+12.2%) |
| Value | $55.4M | $62.2M | +$6.75M (+12.2%) |
New holders (7)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Kim, LLC | 350,000 | $3.48M | 0.17% |
| Barclays PLC | 138,629 | $1.38M | 0.00% |
| Cubist Systematic Strategies, LLC | 52,511 | $521.0K | 0.00% |
| Polar Asset Management Partners Inc. | 50,000 | $496.0K | 0.01% |
| BlackRock Inc. | 5,000 | $50.0K | 0.00% |
| Ancora Advisors, LLC | 2,000 | $20.0K | 0.00% |
| Clear Street LLC | 87 | $1.00K | 0.00% |
Sold out (3)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Spring Creek Capital LLC | 350,000 | $3.47M |
| Mizuho Securities USA LLC | 185,000 | $1.83M |
| Fifth Lane Capital, LP | 50,000 | $496.0K |